Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness - Wikidata - awgldk - TriplyDB

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

http://www.wikidata.org/entity/Q29013141

about

The clinical implications of gene mutations in chronic lymphocytic leukaemia Defects in spliceosomal machinery: a new pathway of leukaemogenesis The significance of spliceosome mutations in chronic lymphocytic leukemia Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution Clinical implications of the molecular genetics of chronic lymphocytic leukemia Misregulation of pre-mRNA alternative splicing in cancer The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia The pathogenesis of chronic lymphocytic leukemia Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond SF3B1 mutations in chronic lymphocytic leukemia.Recurrent mutations refine prognosis in chronic lymphocytic leukemia.SF3B1 mutations constitute a novel therapeutic target in breast cancer.The genetics of uveal melanoma: current insights CircRNAs in hematopoiesis and hematological malignancies Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation.Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.New insights into monoclonal B-cell lymphocytosis.E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity The genomic landscape of chronic lymphocytic leukemia: clinical implications.Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing.U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex.A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.

P2860

Q26749214-0D627D87-D9B3-4A24-B5D6-0367E7250DC2 Q26823040-55F041CF-1C68-4EF4-88B6-0AAAFDA8BB9D Q26823138-896B293B-5331-4A0F-BA87-BD96EC3541CA Q26823586-73134AD0-7426-413C-80B4-41DABB74009C Q26830955-DC99AD8B-7CDF-474F-9E0D-5B893C6C96F0 Q27007114-44CE8063-F4A6-423C-B702-E2DCB6883DBA Q27024411-7E263D50-0FDE-4150-8DA7-D054BFE9D5A6 Q27025715-24AAD1BE-420F-44B4-9874-F5187541B7C2 Q27027493-7C183192-ABB0-45D8-879B-A88AAD0C4C53 Q27852162-A3CB32B9-C046-4FB5-AA97-92ADC97EBB45 Q27853022-CB53E4A3-D35E-415A-BD21-FCE4E5914640 Q27853097-C2BB944F-37B3-49DD-9559-393F23F41833 Q28073150-46FA68E1-167D-46B9-9ABA-561BAB39BEF1 Q28073658-D8A37960-178D-442C-8ABB-7573D75E335A Q28077136-B2887DC5-2FB1-49DB-BFE4-77BE43B40ED8 Q28394721-71901337-8685-41D1-B47F-D7B007112ADD Q30395427-D58CEA73-C310-4797-96E2-DB063DE6D6E1 Q30420265-2077C4B7-A508-4509-AD96-14B6E657D5FF Q30833823-2E8ADAF0-D2DC-46E7-934B-849F19987E49 Q33364071-2155E020-0105-4948-8DEF-71E3507FD12C Q33409149-8903890D-E5E8-44AA-A39D-19723C501423 Q33409459-59D5B811-3509-43D0-A009-9EF2B1D8D808 Q33648906-EB593D0C-BB56-4FD0-9DFB-D2F68A46F365 Q33709543-DBE8BDC8-3995-49B7-8B7E-B65B7E90FA67 Q33781077-9A3024EF-7A55-45DA-9259-8BCADF736755 Q33828825-40BD6CAA-6B6F-47E2-9988-BD3B0E2FA154 Q34047852-43EFDC94-22B3-41A6-BD51-954F19E39AAA Q34195072-3F57AB32-55F2-4446-A182-2FD6D8CC5EF4 Q34256898-1D6A65E4-6E09-4EC2-9713-1B51A25B5A63 Q34595859-EF3024BB-BEFA-4618-A076-E2D3C15A4ADE Q34617633-2AEF8F6C-9DA1-4B41-8AE9-337A61D5CA11 Q34710882-969AFB3C-363B-4B25-B389-6331B6B4BBF2 Q35034303-2EEE9DD5-BB9E-44D1-BEE2-D4897C772164 Q35348356-1AE9A31A-C9FF-499B-B196-25A3F9AA6F48 Q35556982-1B7D0BE2-65C0-4A30-9476-82B13EBBC9D8 Q35690609-713C7ABC-F423-4F01-A579-5CE0C61CF417 Q35741703-297F635E-BBB4-47F6-9D28-89E0BFD93AD2 Q35800840-26B5BC49-F62D-44E3-AA2A-60B068EE4021 Q35822289-1DFB922A-0393-4EE0-989B-7C45404D26A7 Q35860550-349EB9F2-D8E2-43DF-B096-87E1AAC5AAA5

P2860

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

http://www.wikidata.org/entity/Q29013141

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@ast

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@en

type

label

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@ast

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@en

prefLabel

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@ast

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@en

P1433

Q29013141-A2BE4766-D736-4D90-8E22-D4BF30DBA9D0

P1476

Q29013141-58C86B54-549A-4306-80BF-2300F2721D87

P2093

Q29013141-2B856835-22D1-4750-A571-8515EC93F254

Q29013141-2D4026EF-0105-4F1C-A211-029B6EC93B43

Q29013141-322B9D32-C32C-4EFE-9F8D-FE417AF2BC64

Q29013141-33A35410-2AC4-4630-BE1B-582975ADCF48

Q29013141-33EBA54D-0AFA-446A-9BCF-1BD7D5C42DA9

Q29013141-3408E685-6D84-41F2-ABFF-2BE3BE2AA4F2

Q29013141-34C1991C-8C67-43F3-A1E6-4C9A36359286

Q29013141-42685FE4-92A6-4F0A-BB45-A00909DBE24C

Q29013141-80F33ACE-727C-42AF-903B-5796D084B40F

Q29013141-82A835CE-2128-4A1B-A454-2B216FF83417

P2860

Q29013141-115BA515-4014-4047-94DC-B119AE445925

Q29013141-17021133-1F2B-479B-9ACF-52AF46025D5C

Q29013141-1B3EB0E0-EC54-4ADF-9B0A-BDA365FAA594

Q29013141-23C6F517-CD6E-4842-A9AC-1A83223CEE45

Q29013141-2E87456F-F844-4089-84AA-15213BBDCE37

Q29013141-375FCE11-8EAF-4E76-8FD8-A222421A67EA

Q29013141-3ABF4C6E-6DF0-4972-B69E-9369EE8EB75A

Q29013141-4469606C-BC6B-4671-877C-A45B8CE31920

Q29013141-4CB09784-52D9-412E-803F-03F22732815C

Q29013141-5A8E8B93-0416-4770-A1E4-B70997FA69E5

P304

Q29013141-3B88A233-CE54-4C31-8136-21B076DADD94

P31

Q29013141-EBF2C502-6ACF-425D-9E30-F0325686D67F

P3181

Q29013141-0F8F8E01-2218-4017-8302-7BB905AD8866

P356

Q29013141-CFFA6BA6-3EDA-42E0-9C83-B3D199CB5E08

P407

Q29013141-D06236B2-C1FD-4247-B3F5-C4517105541B

P433

Q29013141-1E7CC7ED-BD08-427D-9D15-A2D9B22B72C9

P478

Q29013141-17AC1B7E-F248-415D-94C6-EDB13304C48B

P50

Q29013141-069B35C1-661E-4AFB-B67E-20179EC3E501

Q29013141-271715D1-73AF-4B8B-BCCC-C5E7BE3498F3

Q29013141-3200A361-16CA-4D04-88D7-8A7E40716B7E

Q29013141-8D42CE4E-FEFA-49B9-85AA-F87F86FD2E9D

Q29013141-C0FDB04F-ED03-4026-9A49-45582BF2EEAF

Q29013141-F814A8B2-74A3-4C29-929C-6EB896651842

Q29013141-FF537E3F-7172-4854-A317-D15AEE6F259C

P577

Q29013141-604C2223-178C-4685-AD3A-F36D61B67C78

P5875

Q29013141-FE875C41-123A-422E-872C-23415B61A059

P698

Q29013141-430ED043-BB24-44CF-8747-DA9F87FDC8F8

P921

Q29013141-520ABF9F-A476-441F-81F3-4716483285B6

Q29013141-900507B5-C8FA-49EF-8D1C-744B4D69A2D9

P932

Q29013141-2C9058FD-1A9A-49CD-A556-EF9EEA49C52C

P3181

P356

BLOOD-2011-08-373159

P1433

P1476

Mutations of the SF3B1 splicin ...... and fludarabine-refractoriness

@en

P2093

A. Bruscaggin

http://www.w3.org/2001/XMLSchema#string

A. Guarini

http://www.w3.org/2001/XMLSchema#string

C. Deambrogi

http://www.w3.org/2001/XMLSchema#string

D. Rossi

http://www.w3.org/2001/XMLSchema#string

E. Gargiulo

http://www.w3.org/2001/XMLSchema#string

G. Gaidano

http://www.w3.org/2001/XMLSchema#string

I. Del Giudice

http://www.w3.org/2001/XMLSchema#string

M. Cerri

http://www.w3.org/2001/XMLSchema#string

M. Fangazio

http://www.w3.org/2001/XMLSchema#string

R. Dalla-Favera

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155

Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The pathobiology of splicing

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.

A method and server for predicting damaging missense mutations

The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase.

The spliceosome: design principles of a dynamic RNP machine

Genomic aberrations and survival in chronic lymphocytic leukemia

Chronic lymphocytic leukemia

P304

6904-6908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2766611

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2011-08-373159

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Laura Pasqualucci

Francesco Forconi

Francesco Bertoni

Tiziana Vaisitti

Hossein Khiabanian

P577

2011-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51753834

http://www.w3.org/2001/XMLSchema#string

P698

22039264

http://www.w3.org/2001/XMLSchema#string

P921

P932

3245210

http://www.w3.org/2001/XMLSchema#string